Skye Bioscience, Inc.

Skye Bioscience, Inc. reported a net loss of $55.9 million for fiscal year 2025, driven by significant operating expenses totaling $58.2 million, which resulted in an operating loss of $58.2 million. The company's research and development expenses were $42.4 million, while general and administrative expenses were $15.8 million. Total assets stood at $28.3 million, with current assets of $27.1 million including cash and cash equivalents of $5.9 million and short-term investments of $19.9 million. The company used $43.1 million in cash from operating activities and $19.5 million from investing activities, resulting in a net decrease in cash of $62.5 million. Stockholders' equity was $20.0 million with an accumulated deficit of $186.9 million.

Key Takeaways